
FDA approves Esketamine in the U.S.; sleep apnea surgery reduces risk of car accidents; adults of divorced parents more likely to have strokes – Morning Medical Update
Key Takeaways
- Esketamine nasal spray is the first monotherapy approved for treatment-resistant depression, showing rapid symptom improvement and addressing unmet patient needs.
- Surgery for obstructive sleep apnea significantly reduces motor vehicle accident risk compared to CPAP or no treatment, offering an effective option for select patients.
The top news stories in medicine today.
The U.S. Federal Drug Administration (FDA) has approved esketamine (Spravato; Johnson & Johnson) CIII nasal spray as the first and only monotherapy for adults with treatment-resistant depression (TRD), marking a milestone in mental health treatment. Backed by a priority review, the approval is based on clinical data demonstrating rapid and significant improvement in depressive symptoms compared to placebo, as early as 24 hours, with sustained benefits through four weeks.
Surgery for obstructive sleep apnea (OSA) significantly lowers the risk of motor vehicle accidents (MVAs) compared to use of a Continuous Positive Airway Pressure (CPAP) device or receiving no treatment at all, according to a study published in
Older Americans who experienced parental divorce as children have 60% higher odds of stroke compared to peers whose parents did not get divorced, according to researchers from the University of Toronto, Tyndale University and the University of Texas at Arlington. The study, published in
“While these types of survey-based studies cannot establish causality, we are hoping that our consistent findings will inspire others to examine the topic,”
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.



















